Connect your AI

Ultragenyx Pharmaceutical RARE Net margin

Net margin at other companies

Eli LillyLLY

35%+12.3pp

AmgenAMGN

21%+3.6pp

Ionis PharmaceuticalsIONS

-30.9%-10.5pp

Arrowhead ResearchARWR

-48.4%+240pp

CRISPR TherapeuticsCRSP

-13,856.5%-15,058pp

ModernaMRNA

-143.6%+80.2pp

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

net income/total revenue=-90.9%

Based on trailing twelve months.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's net margin?: Ultragenyx Pharmaceutical (RARE) reported net margin of -90.9% in Q1 2026.
How has Ultragenyx Pharmaceutical's net margin changed year-over-year?: Ultragenyx Pharmaceutical's net margin increased by 2.3% year-over-year, from -93.1% to -90.9%.
What is the long-term trend for Ultragenyx Pharmaceutical's net margin?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's net margin has grown at a 4.4% compound annual growth rate (CAGR), from -68.8% to -85.5%.
What does net margin mean?: Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.